Studying Islatravir/Doravirine for HIV Treatment-Naïve and Experienced PatientsFebruary 27th 2023
“The combination of the 2 drugs was shown in this trial to be noninferior to the standard 3-drug regimen,” said Jean Michel Molina, MD, PhD, lead investigator of Merck’s islatravir/doravirine study.
Hepatitis B Prevention: We Have the Vaccines, But Not the ImplementationFebruary 22nd 2023
Despite effective vaccines and other prevention and treatment modalities, hepatitis B remains a global health challenge. “It’s not for the lack of available tools,” says professor and hepatologist H. Nina Kim, MD, MSc.
Conversations Around Diagnosing HIV, Shaping Treatment ExpectationsFebruary 20th 2023
A clinician offers insights on the initial conversations around learning to treat a chronic disease and the importance behind getting patients started down the right treatment path in the early days following a diagnosis.